These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 309790)

  • 1. Suppression and restoration of cytotoxic T-cell activity during chemotherapy of a mouse T-cell lymphoma and a macrophage tumor.
    Tarnowski GS; Faanes RB; Ralph P; Williams N
    Cancer Res; 1978 Dec; 38(12):4540-5. PubMed ID: 309790
    [No Abstract]   [Full Text] [Related]  

  • 2. Matching of chemotherapy to mouse strain and lymphoid tumor type to prevent tumor-induced suppression of specific T- and B-cell functions.
    Faanes RB; Merluzzi VJ; Williams N; Tarnowski GS; Ralph P
    Cancer Res; 1979 Nov; 39(11):4564-74. PubMed ID: 315269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes.
    Schorlemmer HU; Bosslet K; Sedlacek HH
    Cancer Res; 1983 Sep; 43(9):4148-53. PubMed ID: 6871856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
    Correale P; Del Vecchio MT; La Placa M; Montagnani F; Di Genova G; Savellini GG; Terrosi C; Mannucci S; Giorgi G; Francini G; Cusi MG
    J Immunother; 2008; 31(2):132-47. PubMed ID: 18481383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical model.
    De Boer RJ; Hogeweg P; Dullens HF; De Weger RA; Den Otter W
    J Immunol; 1985 Apr; 134(4):2748-58. PubMed ID: 3156189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.
    Fujii T; Igarashi T; Kishimoto S
    J Natl Cancer Inst; 1987 Mar; 78(3):509-17. PubMed ID: 2950265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of adult thymectomy on the growth of 203-glioma in mice--analysis of T cell subpopulation in tumor immunology].
    Yamasaki T; Yamashita J; Handa H; Namba Y; Hanaoka M
    No To Shinkei; 1982 Nov; 34(11):1067-75. PubMed ID: 6984337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S; Yamamoto H; Fujii Y; Arai S
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of T lymphocytes in vitro by syngeneic macrophages fed with tumor antigens.
    Treves AJ; Schechter B; Cohen IR; Feldman M
    J Immunol; 1976 Apr; 116(4):1059-64. PubMed ID: 1082902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of RFM mouse T lymphocyte anti-oncofetal antigen immunity in apparent tumor-free, long-term survivors of sublethal X-irradiation by limiting dilution T lymphocyte cloning.
    Rohrer JW; Culpepper C; Barsoum AL; Coggin JH
    J Immunol; 1995 Mar; 154(5):2266-80. PubMed ID: 7868899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The immunomodulator thymalin in the experimental chemotherapy of tumors].
    Amosova EN; Iaremenko KV; Cherdyntseva NV; Nikolin VP; Ogreba VI
    Vopr Onkol; 1987; 33(10):68-72. PubMed ID: 3686911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
    Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
    Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukemia virus-induced immunosuppression. X. Depression of T cell-mediated cytotoxicity after infection of mice with Friend leukemia virus.
    Mortensen RF; Ceglowski WS; Friedman H
    J Immunol; 1974 Jun; 112(6):2077-86. PubMed ID: 4207729
    [No Abstract]   [Full Text] [Related]  

  • 14. Lectin-induced nonlethal adhesions between cytolytic T lymphocytes and antigenically unrecognizable tumor cells and nonspecific "triggering" of cytolysis.
    Parker WL; Martz E
    J Immunol; 1980 Jan; 124(1):25-35. PubMed ID: 6765968
    [No Abstract]   [Full Text] [Related]  

  • 15. Suppression of T-cell mediated lymphokine production but not cytotoxic activity by macrophages.
    Varesio L; Eva A; Cavallo G; Herberman RB
    Boll Ist Sieroter Milan; 1980 Mar; 59(1):12-6. PubMed ID: 6970038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional cytotoxic T lymphocyte hybridomas.
    Kaufmann Y; Berke G; Eshhar Z
    Transplant Proc; 1981 Mar; 13(1 Pt 2):1170-4. PubMed ID: 6973859
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization of the effects of endotoxin on macrophage tumor cell killing.
    Weinberg JB; Chapman HA; Hibbs JB
    J Immunol; 1978 Jul; 121(1):72-80. PubMed ID: 27559
    [No Abstract]   [Full Text] [Related]  

  • 18. A T-dependent factor in mouse serum suppressing lymphocytic anti-tumor cytotoxicity.
    Rao PE; Sussdorf DH
    Immunology; 1978 Dec; 35(6):907-15. PubMed ID: 310808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition by selected anticancer agents of the development of primary cell-mediated immunity against allogeneic tumor cells in culture.
    Orsini F; Eppolito C; Ehrke MJ; Mihich E
    Cancer Treat Rep; 1980; 64(2-3):211-8. PubMed ID: 6967756
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunomodulation by adriamycin.
    Mihich E
    Sci Rep Res Inst Tohoku Univ Med; 1985 Dec; 32(1-4):10-3. PubMed ID: 3915832
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.